Takotsubo cardiomyopathy, or Takotsubo syndrome, can be quite rare found, but however the frequency of diagnosing with this disease among patients of cardiology departments is constantly growing. On the one hand, this may be due to improved diagnostics of this pathology, and on the other hand, to an increasing frequency of mental disorders in the human population and the spread of other risk factors, including drug-induced variants. The pathogenesis of the development of Takotsubo cardiomyopathy is associated with an increase in the level of catecholamines, which may be the result of a reactive sympathetic enhancement in response to external factors or be the result of taking antidepressants that can produce a similar effect. Although the diagnostics of this pathology has made significant progress, but however there is still no consensus on the strategy of treatment. This is due to the lack of large-scale randomized prospective studies that could justify one or another therapeutic approach. Basically, the efforts of medical doctors are aimed at maintaining cardiac activity, eliminating the trigger of the disease and at treating complications. The purpose of this review was to summarize the accumulated information related to the problems of etiology, pathogenesis, diagnosis and treatment of Takotsubo cardiomyopathy with an emphasis on the variants associated with the use of antidepressants.